L
Luca Piccoli
Researcher at University of Lugano
Publications - 68
Citations - 6355
Luca Piccoli is an academic researcher from University of Lugano. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 25, co-authored 58 publications receiving 3010 citations. Previous affiliations of Luca Piccoli include ETH Zurich & World Health Organization.
Papers
More filters
Journal ArticleDOI
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Luca Piccoli,Young-Jun Park,M. Alejandra Tortorici,M. Alejandra Tortorici,Nadine Czudnochowski,Alexandra C. Walls,Martina Beltramello,Chiara Silacci-Fregni,Dora Pinto,Laura E. Rosen,John E. Bowen,Oliver J. Acton,Stefano Jaconi,Barbara Guarino,Andrea Minola,Fabrizia Zatta,Nicole Sprugasci,Jessica Bassi,Alessia Peter,Anna De Marco,Jay C. Nix,Federico Mele,Sandra Jovic,Blanca Fernandez Rodriguez,Sneha V. Gupta,Feng Jin,Giovanni Piumatti,Giovanni Piumatti,Giorgia Lo Presti,Alessandra Franzetti Pellanda,Maira Biggiogero,Maciej Tarkowski,Matteo Samuele Pizzuto,Elisabetta Cameroni,Colin Havenar-Daughton,Megan Smithey,David K. Hong,Valentino Lepori,Emiliano Albanese,Alessandro Ceschi,Alessandro Ceschi,Enos Bernasconi,Luigia Elzi,Paolo Ferrari,Christian Garzoni,Agostino Riva,G. Snell,Federica Sallusto,Katja Fink,Herbert W. Virgin,Antonio Lanzavecchia,Davide Corti,David Veesler +52 more
TL;DR: It is found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores, and the immunodominance of the receptor-binding motif will guide the design of COVID-19 vaccines and therapeutics.
Journal ArticleDOI
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Petra Mlcochova,Steven Kemp,Steven Kemp,Mahesh Shanker Dhar,Guido Papa,Bo Meng,Isabella Ferreira,Rawlings Datir,Dami A. Collier,Dami A. Collier,Anna Albecka,Sujeet Kumar Singh,Rajesh Pandey,Jonathan Brown,Jie Zhou,Niluka Goonawardane,Swapnil Mishra,Charles Whittaker,Thomas A. Mellan,Robin Marwal,Meena Datta,Shantanu Sengupta,Kalaiarasan Ponnusamy,V. S. Radhakrishnan,Adam Abdullahi,Oscar Charles,Partha Chattopadhyay,Priti Devi,Daniela Caputo,Thomas P. Peacock,Chand Wattal,Neeraj Goel,Ambrish Satwik,Raju Vaishya,Meenakshi Agarwal,Antranik Mavousian,Joo-Hyeon Lee,Jessica Bassi,Chiara Silacci-Fegni,Christian Saliba,Dora Pinto,Takashi Irie,Isao Yoshida,William L Hamilton,Kei Sato,Samir Bhatt,Samir Bhatt,Seth Flaxman,Leo C. James,Davide Corti,Luca Piccoli,Wendy S. Barclay,Partha Rakshit,Anurag Agrawal,Ravindra K. Gupta +54 more
TL;DR: The B.617.1.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike as discussed by the authors.
Journal ArticleDOI
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Dami A. Collier,Dami A. Collier,Anna De Marco,Isabella Ferreira,Bo Meng,Rawlings Datir,Rawlings Datir,Alexandra C. Walls,Steven Kemp,Steven Kemp,Jessica Bassi,Dora Pinto,Chiara Silacci-Fregni,Siro Bianchi,M. Alejandra Tortorici,John E. Bowen,Katja Culap,Stefano Jaconi,Elisabetta Cameroni,Gyorgy Snell,Matteo Samuele Pizzuto,Alessandra Franzetti Pellanda,Christian Garzoni,Agostino Riva,Anne Elmer,Nathalie Kingston,Barbara J. Graves,Laura E. McCoy,Kenneth G. C. Smith,John Bradley,Nigel J. Temperton,Lourdes Ceron-Gutierrez,Gabriela Barcenas-Morales,William T. Harvey,Herbert W. Virgin,Antonio Lanzavecchia,Luca Piccoli,Rainer Doffinger,Mark R. Wills,David Veesler,Davide Corti,Ravindra K. Gupta +41 more
TL;DR: In this article, the authors assessed the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22.1.7 and found that the emergence of the E484K substitution in a B.1, 1.1., 1.7 background represents a threat to the efficacy of the BNT 162b2 vaccine.
Journal ArticleDOI
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
E. Thomson,E. Thomson,Laura E. Rosen,James G Shepherd,Roberto Spreafico,Ana da Silva Filipe,Jason A. Wojcechowskyj,Chris Davis,Luca Piccoli,David J Pascall,Josh Dillen,Spyros Lytras,Nadine Czudnochowski,Rajiv Shah,Marcel Meury,Natasha Jesudason,Anna De Marco,Kathy Li,Jessica Bassi,Áine O'Toole,Dora Pinto,Rachel M. Colquhoun,Katja Culap,Ben Jackson,Fabrizia Zatta,Andrew Rambaut,Stefano Jaconi,Vattipally B. Sreenu,Jay C. Nix,Ivy Zhang,Ivy Zhang,Ruth F. Jarrett,William G. Glass,Martina Beltramello,Kyriaki Nomikou,Matteo Samuele Pizzuto,Lily Tong,Elisabetta Cameroni,Tristan I. Croll,Natasha Johnson,Julia di Iulio,Arthur Wickenhagen,Alessandro Ceschi,Alessandro Ceschi,Aoife M. Harbison,Daniel Mair,Paolo Ferrari,Katherine Smollett,Federica Sallusto,Federica Sallusto,Stephen Carmichael,Christian Garzoni,Jenna Nichols,Massimo Galli,Joseph Hughes,Agostino Riva,Antonia Ho,Marco Schiuma,Malcolm G Semple,Malcolm G Semple,Peter J. M. Openshaw,Elisa Fadda,J Kenneth Baillie,John D. Chodera,Suzannah J. Rihn,Samantha Lycett,Herbert W. Virgin,Amalio Telenti,Davide Corti,David Robertson,Gyorgy Snell +70 more
TL;DR: In this paper, the authors demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K.
Journal ArticleDOI
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Matthew McCallum,Jessica Bassi,Anna De Marco,Alexander Chen,Alexandra C. Walls,Julia di Iulio,M. Alejandra Tortorici,Mary-Jane Navarro,Chiara Silacci-Fregni,Christian Saliba,Kaitlin R. Sprouse,Maria De Agostini,Dora Pinto,Katja Culap,Siro Bianchi,Stefano Jaconi,Elisabetta Cameroni,John E. Bowen,Sasha W Tilles,Matteo Samuele Pizzuto,Sonja Bernasconi Guastalla,Giovanni Bona,Alessandra Franzetti Pellanda,Christian Garzoni,Wesley C. Van Voorhis,Laura E. Rosen,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Luca Piccoli,Davide Corti,David Veesler +31 more
TL;DR: In this paper, a novel variant of concern (VOC) named CAL.20C (B.1.427/B. 1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).